Generic drug manufacturer
said on Tuesday it has received Food and Drug Administration clearance to manufacture and market Desoximetasone Gel 0.05%.
The gel, used for the relief of inflammatory skin conditions, is the genric equivalent to Taro Pharmaceutical's Topicort Gel 0.05%. That product has an annual U.S. market of approximately $4 million, according to NDC data.
The company is a leading global healthcare supplier and the world's largest manufacturer of over-the-counter pharmaceutical and nutritional products for the store brand market.
The stock was up 21 cents to $16.06 at midday Wednesday.
This story was created through a joint venture between TheStreet.com and IRIS.